Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia
Investigational drug revumenib now under review at FDA for <em>KMT2A</em>-rearranged disease
Source: medpagetoday.com
Stay updated with breaking news from Junh Choi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investigational drug revumenib now under review at FDA for <em>KMT2A</em>-rearranged disease